176 related articles for article (PubMed ID: 32525730)
41. Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting.
Cunningham K; DiFilippo H; Henes K; Irwin LL; Napier E; Weber E
Semin Oncol Nurs; 2021 Aug; 37(4):151178. PubMed ID: 34340892
[TBL] [Abstract][Full Text] [Related]
42. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.
O'Leary MC; Lu X; Huang Y; Lin X; Mahmood I; Przepiorka D; Gavin D; Lee S; Liu K; George B; Bryan W; Theoret MR; Pazdur R
Clin Cancer Res; 2019 Feb; 25(4):1142-1146. PubMed ID: 30309857
[TBL] [Abstract][Full Text] [Related]
43. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
44. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
[TBL] [Abstract][Full Text] [Related]
45. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
46. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Pasquini MC; Hu ZH; Curran K; Laetsch T; Locke F; Rouce R; Pulsipher MA; Phillips CL; Keating A; Frigault MJ; Salzberg D; Jaglowski S; Sasine JP; Rosenthal J; Ghosh M; Landsburg D; Margossian S; Martin PL; Kamdar MK; Hematti P; Nikiforow S; Turtle C; Perales MA; Steinert P; Horowitz MM; Moskop A; Pacaud L; Yi L; Chawla R; Bleickardt E; Grupp S
Blood Adv; 2020 Nov; 4(21):5414-5424. PubMed ID: 33147337
[TBL] [Abstract][Full Text] [Related]
47. Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis.
Carey N; Leahy J; Trela-Larsen L; McCullagh L; Barry M
Int J Technol Assess Health Care; 2022 Jul; 38(1):e56. PubMed ID: 35815435
[TBL] [Abstract][Full Text] [Related]
48. Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
V Stackelberg A; Jäschke K; Jousseaume E; Templin C; Jeratsch U; Kosmides D; Steffen I; Gökbuget N; Peters C
Leukemia; 2023 Dec; 37(12):2346-2355. PubMed ID: 37880478
[TBL] [Abstract][Full Text] [Related]
49. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR; Dickinson M; Purtill D; Barba P; Santoro A; Hamad N; Kato K; Sureda A; Greil R; Thieblemont C; Morschhauser F; Janz M; Flinn I; Rabitsch W; Kwong YL; Kersten MJ; Minnema MC; Holte H; Chan EHL; Martinez-Lopez J; Müller AMS; Maziarz RT; McGuirk JP; Bachy E; Le Gouill S; Dreyling M; Harigae H; Bond D; Andreadis C; McSweeney P; Kharfan-Dabaja M; Newsome S; Degtyarev E; Awasthi R; Del Corral C; Andreola G; Masood A; Schuster SJ; Jäger U; Borchmann P; Westin JR
N Engl J Med; 2022 Feb; 386(7):629-639. PubMed ID: 34904798
[TBL] [Abstract][Full Text] [Related]
50. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
51. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
Vairy S; Garcia JL; Teira P; Bittencourt H
Drug Des Devel Ther; 2018; 12():3885-3898. PubMed ID: 30518999
[TBL] [Abstract][Full Text] [Related]
52. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
[TBL] [Abstract][Full Text] [Related]
53. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
[TBL] [Abstract][Full Text] [Related]
54. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
Appl Health Econ Health Policy; 2024 Apr; ():. PubMed ID: 38683438
[TBL] [Abstract][Full Text] [Related]
55. More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
Tong WH; Mertens BJ
J Clin Oncol; 2023 May; 41(13):2450-2451. PubMed ID: 36898080
[No Abstract] [Full Text] [Related]
56. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Moskop A; Pommert L; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston ML; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Guest EM; Breese EH; Schultz LM
Blood Adv; 2022 Jul; 6(14):4251-4255. PubMed ID: 35580324
[TBL] [Abstract][Full Text] [Related]
57. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
Thomas X; Paubelle E
Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
[TBL] [Abstract][Full Text] [Related]
58. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Thudium Mueller K; Grupp SA; Maude SL; Levine JE; Pulsipher MA; Boyer MW; August KJ; Myers GD; Tam CS; Jaeger U; Foley SR; Borchmann P; Schuster SJ; Waller EK; Awasthi R; Potthoff B; Warren A; Waldron ER; McBlane F; Chassot-Agostinho A; Laetsch TW
Blood Adv; 2021 Dec; 5(23):4980-4991. PubMed ID: 34432863
[TBL] [Abstract][Full Text] [Related]
59. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
Leahy AB; Elgarten CW; Grupp SA; Maude SL; Teachey DT
Expert Rev Anticancer Ther; 2018 Oct; 18(10):959-971. PubMed ID: 30111196
[TBL] [Abstract][Full Text] [Related]
60. Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.
Verneris MR; Ma Q; Zhang J; Keating A; Tiwari R; Li J; Yang H; Agarwal A; Pacaud L
Blood Adv; 2021 Dec; 5(23):5387-5395. PubMed ID: 34597381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
